The latest news about the CMCiB. For more news of research at the IGTP, please see our main website.

IGTP premieres the podcast ‘Un bri de ciència’

In the first episode, "La tuberculosi: la pandèmia dels pobres" (Tuberculosis: the pandemic of the poor), researcher José Domínguez explains the basics of the disease and the current situation of research. This podcast is a way for the centre to reach a wide audience, thanks to a short and dynamic storytelling format.

The Clinical and Environmental Infectious Diseases Research Group signs a collaboration for the development of a new biocide for the treatment of drinking water

The Clinical and Environmental Infectious Diseases Research Group (CEID) has discovered a molecule of natural origin with a high bactericidal, amoebicidal and biofilm reduction capacity. The collaboration signed by the group's researchers with a private company will finance the improvement of the molecule's characteristics to be applied in large water installations, preventing water for human consumption from acting as a vehicle for the transmission of bacterial diseases.

Mesenchymal stem cells reveal mechanisms of action in regulatory B cells independent of interleukin-10 useful for their identification and monitoring

Researchers from the REMAR-IVECAT ("Kidney Related Diseases Research" and "Innovation in VEsicles and Cells for Application in Therapy") group, from the Germans Trias i Pujol Research Institute (IGTP), identify molecular pathways in regulatory B cells that are essential for their therapeutic applications. In the article that has been recently published in Frontiers in Immunology, the use of mesenchymal stem cells has allowed distinguishing the molecules that are essential to monitoring regulatory B cells in kidney transplants. 

The IGTP coordinating two out of nine COST Actions coming to Spain and participating in a third

The COST Programme (European Cooperation in Science and Technology) has approved 70 new actions and Spain is coordinating nine of them, making it second in the ranking of countries leading COST Actions after Italy, which is coordinating ten. Three of the Spanish projects are from the Germans Trias i Pujol Research Institute (IGTP) and two of these are being led by the IGTP. COST Actions run for four years and this round will start in the coming autumn.

Bioimplants with extra-cellular vesicles from stem cells can improve cardiac function after an acute myocardial heart attack

Researchers from the ICREC Group (Cardiac Insufficiency and Regeneration) in cardiovascular diseases at the Germans Trias i Pujol Research Institute (IGTP) continue to work on therapeutic technologies to repair cardiac tissue after a heart attack. In an article published in Theranostics, they present a study of extracellular vesicles from mesenchymal stem cells combined with tissue engineering as a therapy to repair the heart after a heart attack. They have carried out the study on a porcine heart attack model at the Centre for Comparative Medicine and Bioimage (CMCiB) at the IGTP.

The CMCiB awarded the certificate for Good Laboratory Practice (GLP) for preclinical research

The Centre for Comparative Medicine and Bioimage (CMCiB) of the Germans Trias I Pujol Research Institute has been awarded the certificate for complying with good laboratory practices (GLP) in line with the European Directive 2004/9/CE. The centre complies with the principles established by the Spanish Royal Decree 822/19932 for carrying out preclinical studies with healthcare products (analytical tests, clinical chemistry - haematology and biochemistry - in studies administrating trial products, obtaining samples and biocompatibility of healthcare products). The areas certified are the surgical and bioimage areas, including the technology of vascular radiology interventions, ultrasound scan and magnetic resonance.